The Molecule That Says Lyme Never Left

New research keeps finding the Lyme bacterium’s cell wall long after treatment. Something is still making it.

New findings: researchers keep detecting a piece of the Lyme bacterium in patients long after their antibiotics end. To me, that points in one direction — The infection isn’t always gone.

At least one in five people treated for Lyme don’t fully recover. Some studies put it at one in four or higher. Fatigue, pain, brain fog — Months, sometimes years later. The low numbers you’ll see quoted understate it.

For decades, these patients were told the bacteria were cleared & the symptoms were something else. That’s a hard position to defend. More than a dozen studies have recovered live Borrelia from humans despite months — Even several years — Of antibiotic treatment. The organism has been cultured & seen. It persists.

The newest piece comes from a Northwestern team led by Dr. Brandon Jutras. They found peptidoglycan — The molecule that forms bacterial cell walls — In the liver & in the joint fluid of Lyme arthritis patients, weeks to months after treatment ended.

The researchers frame it as leftover debris. I read it differently. Nearly every bacterium builds its wall from peptidoglycan, & the body clears it quickly — It isn’t a molecule that sits around for more than a few months. So its presence raises the obvious question: what’s still producing it?

The straightforward answer is that live bacteria survived the antibiotics & are still making it. On that view, peptidoglycan isn’t the cause of the symptoms so much as the fingerprint — A marker that the infection is ongoing. That fits the culture data. It fits what patients have described for years.

The distinction changes how you treat. If this is chronic infection, calming inflammation alone won’t be enough — You have to reach the bacteria that standard courses miss. But the immune side matters too. A Tulane team recently showed that FGFR inhibitors — Drugs first studied in cancer — Sharply reduced nerve inflammation & cell death in infected tissue. Both angles are worth pursuing.

None of this is fully settled. But the evidence is real, measurable, & consistent — & It lands where patients have been pointing all along. For some, Lyme doesn’t leave. That’s not a small thing.

Sources: Northwestern University Feinberg School of Medicine, published in Science Translational Medicine; Tulane University, published in Frontiers in Immunology.